Compare · ALVO vs ARGX
ALVO vs ARGX
Side-by-side comparison of Alvotech (ALVO) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALVO and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $65.72B, about 34.5x ALVO ($1.91B).
- Over the past year, ALVO is down 39.1% and ARGX is up 50.2% - ARGX leads by 89.3 points.
- ARGX has been more active in the news (15 items in the past 4 weeks vs 8 for ALVO).
- ARGX has more recent analyst coverage (25 ratings vs 12 for ALVO).
- Company
- Alvotech
- argenx SE
- Price
- $4.89-0.20%
- $1058.90+1.10%
- Market cap
- $1.91B
- $65.72B
- 1M return
- +38.72%
- +19.92%
- 1Y return
- -39.14%
- +50.16%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 8
- 15
- Recent ratings
- 12
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ALVO
- Alvotech to present at upcoming investor conferences in September
- BofA Securities initiated coverage on Alvotech with a new price target
- SEC Form 6-K filed by Alvotech
- Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
- SEC Form 6-K filed by Alvotech
- Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
- Evercore ISI initiated coverage on Alvotech
- Alvotech to Report Financial Results for H1 2026
- SEC Form 6-K filed by Alvotech
- Alvotech announces successful closure of FDA inspection of manufacturing facility
Latest ARGX
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE